一项回顾性单中心研究:姑息性分割疗程放疗(PASCORA)方案对非转移性头颈癌患者姑息性治疗的有效性

Umesh Velu, P. Shetty, Anshul Singh, S. Salins, K. Sharan
{"title":"一项回顾性单中心研究:姑息性分割疗程放疗(PASCORA)方案对非转移性头颈癌患者姑息性治疗的有效性","authors":"Umesh Velu, P. Shetty, Anshul Singh, S. Salins, K. Sharan","doi":"10.31557/apjcb.2022.7.4.315-322","DOIUrl":null,"url":null,"abstract":"Introduction: We at our centre practice a PAlliative Split COurse RAdiotherapy (PASCORA) of 22.5Gy in 5 fractions followed by a gap of 4 weeks and then again repeat 22.5Gy in 5 fractions for locally advanced squamous cell carcinoma patients treated with a palliative intent. Aim was t0 assess the symptomatic relief at 3 months following PASCORA regimen. Materials & Methods: 49 Patients with LAHNSCC between January 2014 to January 2021, planned for PASCORA regimen were evaluated. Symptomatic relief was assessed on an objective scale. OS was determined using Kaplan Meir survival curves. Results: Median age was 61 years, multiple comorbidities (37%) were the most commonly documented reason for these patients being treated with a palliative intent. 25% of our patients had an excellent symptomatic relief, 26% of our patients had a good symptomatic relief and 31% had a partial relief. Median OS was 38 months in patients who had an excellent symptomatic relief and 3-8 months in patients with no or partial symptomatic relief ( p value=0.000) 6% of our patients had Grade 3 /4 RTOG toxicity. Conclusion: PASCORA regimen offers a good symptomatic relief with good local control rates and acceptable level of toxicity and comparable OS.","PeriodicalId":8848,"journal":{"name":"Asian Pacific Journal of Cancer Biology","volume":"19 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Effectiveness of PAlliative Split COurse RAdiotherapy (PASCORA) Regimen in Non-metastatic Head and Neck Cancer Patients who are Treated with Palliative Intent- A Retrospective Single Centre Study\",\"authors\":\"Umesh Velu, P. Shetty, Anshul Singh, S. Salins, K. Sharan\",\"doi\":\"10.31557/apjcb.2022.7.4.315-322\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: We at our centre practice a PAlliative Split COurse RAdiotherapy (PASCORA) of 22.5Gy in 5 fractions followed by a gap of 4 weeks and then again repeat 22.5Gy in 5 fractions for locally advanced squamous cell carcinoma patients treated with a palliative intent. Aim was t0 assess the symptomatic relief at 3 months following PASCORA regimen. Materials & Methods: 49 Patients with LAHNSCC between January 2014 to January 2021, planned for PASCORA regimen were evaluated. Symptomatic relief was assessed on an objective scale. OS was determined using Kaplan Meir survival curves. Results: Median age was 61 years, multiple comorbidities (37%) were the most commonly documented reason for these patients being treated with a palliative intent. 25% of our patients had an excellent symptomatic relief, 26% of our patients had a good symptomatic relief and 31% had a partial relief. Median OS was 38 months in patients who had an excellent symptomatic relief and 3-8 months in patients with no or partial symptomatic relief ( p value=0.000) 6% of our patients had Grade 3 /4 RTOG toxicity. Conclusion: PASCORA regimen offers a good symptomatic relief with good local control rates and acceptable level of toxicity and comparable OS.\",\"PeriodicalId\":8848,\"journal\":{\"name\":\"Asian Pacific Journal of Cancer Biology\",\"volume\":\"19 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-12-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Asian Pacific Journal of Cancer Biology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.31557/apjcb.2022.7.4.315-322\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Pacific Journal of Cancer Biology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31557/apjcb.2022.7.4.315-322","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

简介:我们在我们的中心实践姑息性分割疗程放疗(PASCORA) 22.5Gy,分5次,间隔4周,然后再次重复22.5Gy,分5次,用于局部晚期鳞状细胞癌患者的姑息性治疗。目的是评估PASCORA方案后3个月的症状缓解情况。材料与方法:对2014年1月至2021年1月计划接受PASCORA方案治疗的49例LAHNSCC患者进行评估。以客观量表评估症状缓解程度。采用Kaplan Meir生存曲线测定OS。结果:中位年龄为61岁,多重合并症(37%)是这些患者接受姑息治疗的最常见原因。25%的患者有很好的症状缓解,26%的患者有很好的症状缓解,31%的患者有部分缓解。症状缓解良好的患者中位生存期为38个月,没有或部分症状缓解的患者中位生存期为3-8个月(p值=0.000),6%的患者为3 /4级RTOG毒性。结论:PASCORA方案具有良好的症状缓解、良好的局部控制率、可接受的毒性水平和相当的总生存期。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
The Effectiveness of PAlliative Split COurse RAdiotherapy (PASCORA) Regimen in Non-metastatic Head and Neck Cancer Patients who are Treated with Palliative Intent- A Retrospective Single Centre Study
Introduction: We at our centre practice a PAlliative Split COurse RAdiotherapy (PASCORA) of 22.5Gy in 5 fractions followed by a gap of 4 weeks and then again repeat 22.5Gy in 5 fractions for locally advanced squamous cell carcinoma patients treated with a palliative intent. Aim was t0 assess the symptomatic relief at 3 months following PASCORA regimen. Materials & Methods: 49 Patients with LAHNSCC between January 2014 to January 2021, planned for PASCORA regimen were evaluated. Symptomatic relief was assessed on an objective scale. OS was determined using Kaplan Meir survival curves. Results: Median age was 61 years, multiple comorbidities (37%) were the most commonly documented reason for these patients being treated with a palliative intent. 25% of our patients had an excellent symptomatic relief, 26% of our patients had a good symptomatic relief and 31% had a partial relief. Median OS was 38 months in patients who had an excellent symptomatic relief and 3-8 months in patients with no or partial symptomatic relief ( p value=0.000) 6% of our patients had Grade 3 /4 RTOG toxicity. Conclusion: PASCORA regimen offers a good symptomatic relief with good local control rates and acceptable level of toxicity and comparable OS.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Investigating the Properties and Cytotoxicity of Cisplatin-Loaded Nano-Polybutylcyanoacrylate on Breast Cancer Cells Rectal Polyp Prolapse: A Case Report Voided Urine Sample in the Diagnosis of Prostate Cancer in Patients with Serum PSA Ranging between 2.6 to 10 ng/mL Review on Automated Skin Cancer Detection Using Image Processing Techniques Oral Cancer at a Glance
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1